.jpg)
Wellumio is transforming stroke care with portable brain scans to rapidly detect acute stroke that cuts diagnosis time and unlocks treatment in the ‘golden hour’ when every second counts
WELLINGTON, New Zealand, September 16, 2025 - Wellumio, a New Zealand-based medical technology company pioneering the future of stroke diagnostics with its portable neuroimaging device, Axana®, for rapid, point-of-care detection of stroke, is seeking investors to accelerate its breakthrough solution.
Currently, less than 5% of stroke patients receive treatment within the critical 'golden hour' when the chance of disability free survival is highest – and access to fast, accurate diagnosis tools can significantly improve diagnosis, treatment and outcomes. Wellumio’s Axana scanner brings advanced neuroimaging to the patient’s bedside to detect acute stroke biomarkers - reducing diagnosis time by over 90% and providing critical insights into the severity and extent of stroke-related damage.
Wellumio’s Snowball Effect crowdfunding equity investment campaign launched today to give an opportunity to invest alongside existing shareholders including Nuance Capital, Movac, Icehouse Ventures, Cure Kids Ventures, NZ Growth Capital Partners (NZGCP)’s Aspire Seed Fund, Outset Ventures and Booster Innovation Fund.
For more information on Wellumio, visit www.wellumio.com, and on the Snowball Effect equity investment campaign, visit https://www.snowballeffect.co.nz/offers/preview/wellumio-f1his
